Introduction Application of artificial intelligence (AI) tools in the healthcare setting gains importance especially in the domain of disease diagnosis. Numerous studies have tried to explore AI in ...

It’s been three years since OpenAI released ChatGPT and kicked off a surge in innovation and attention on AI. Since then, optimists have regularly claimed that AI will become a critical part of the ...

Recursion Pharmaceuticals (NASDAQ: RXRX) experienced an 11% increase in stock price on Wednesday after JP Morgan raised its rating, noting the promising potential of its MEK inhibitor program. However ...

It’s happened to all of us: you find the perfect model for your needs — a bracket, a box, a cable clip, but it only comes in STL, and doesn’t quite fit. That problem will never happen if you’re using ...

Abstract: This paper proposes a new method to estimate the parameters of both blocks, linear and nonlinear using an iterative and recursive subspace approaches. More importantly, in an attempt to show ...

Recursion Pharmaceuticals remains a high-cash-burn, premium-valued biotech with unproven clinical success despite a recent 47% rally. RXRX's next 18 months are catalyst-rich, but key pipeline assets ...

Most startups don't die because they lack vision but because they misread early signals. Lack of demand is why 42% of startups fail, and it’s a problem that founders can spot before launch. Quibi is a ...

The 2026 Coachella Valley Music and Arts Festival lineup has been unveiled. Sabrina Carpenter, Justin Bieber, and Karol G are heading to the desert next year as the festival’s headliners, topping the ...

RXRX stock looks like a deep-value growth bet at just $5 and change. Though the technology is exciting, I’m not rushing into shares just yet. Nvidia made early investors rich, but there is a new class ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q2 2025 Earnings Call Transcript August 5, 2025 Recursion Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.41187 EPS, ...